Geode Capital Management
AARD

Geode Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Geode Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Sell
149,844
-159,605
-52% -$746K ﹤0.01% 3411
2026
Q1 		$1.17M Buy
309,449
+11,584
+4% +$120K ﹤0.01% 3311
2025
Q4 		$3.91M Buy
297,865
+103,830
+54% +$1.3M ﹤0.01% 2897
2025
Q3 		$2.58M Buy
194,035
+57,108
+42% +$644K ﹤0.01% 3098
2025
Q2 		$1.85M Buy
136,927
+77,327
+130% +$797K ﹤0.01% 3170
2025
Q1 		$448K Buy
+59,600
New +$669K ﹤0.01% 3585

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management's AARD Position: Q2 2026 in Review

Geode Capital Management reduced its Aardvark Therapeutics (AARD) stake by 52% in Q2 2026, selling an estimated $746K and leaving 149,844 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #3411.

Geode Capital Management first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.91M in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Geode Capital Management held 149,844 shares of Aardvark Therapeutics worth $864K as of Q2 2026.
  • Geode Capital Management sold 159,605 Aardvark Therapeutics shares in Q2 2026, an estimated $746K.
  • Aardvark Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3411 holding.
  • Geode Capital Management first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Geode Capital Management's Aardvark Therapeutics position peaked at $3.91M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.